Meeting
2024 ASCO Annual Meeting
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
Presenter
Shubham Pant, MD, MBBS
The University of Texas MD Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04466891
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4091)
DOI
10.1200/JCO.2024.42.16_suppl.4091
Abstract #
4091
Poster Bd #
71
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Zanidatamab (zani) in previously treated HER2+ biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study.
Speaker: Shubham Pant, MD, MBBS
Videos & Slides
2023 ASCO Annual Meeting
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).
Speaker: Shubham Pant, MD
Videos & Slides
2021 ASCO Annual Meeting
Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).
Speaker: Changhoon Yoo, MD, PhD
Videos & Slides
2021 Gastrointestinal Cancers Symposium
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
Speaker: Funda Meric-Bernstam, MD